Long-term follow-up for Duchenne patients treated before
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study checks how people with Duchenne muscular dystrophy are doing long-term after receiving delandistrogene moxeparvovec (SRP-9001) in an earlier trial. It helps researchers understand the long-term safety and effects of that treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously received delandistrogene moxeparvovec (SRP-9001) for Duchenne muscular dystrophy in a clinical study
- You are able to follow the study visit schedule and other study instructions
- Either you have a parent/legal caregiver who can help with visits, or you are 18 or older
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a gene therapy that aims to help muscles produce a protein they are missing. It is for people with Duchenne muscular dystrophy who are no longer able to walk, and it may help slow the progression of the disease.
This long-term follow-up study watches people who previously received the experimental gene therapy RGX-202 for Duchenne muscular dystrophy. It checks how patients are doing over time and does not involve any new treatment.
This study compares the gene therapy ELEVIDYS (delandistrogene moxeparvovec) to usual treatments for people with Duchenne muscular dystrophy (DMD). It helps researchers understand how well ELEVIDYS works over time in real-world settings.
This trial tests a new gene therapy called SGT-003 for children with Duchenne muscular dystrophy. It aims to help the body produce a working version of dystrophin, the protein missing in Duchenne.
This trial tests a gene therapy called GNR-097 for boys with Duchenne muscular dystrophy (DMD). The therapy aims to help improve muscle function, and the study will check how safe and effective it is.
This trial looks at how safely givinostat works over a longer time in people with Duchenne muscular dystrophy (DMD). It mainly checks long-term side effects and tolerability, especially in a specific subgroup of muscle fat levels.
Hear when a new Duchenne Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.